Cargando…

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis

Mucopolysaccharidosis (MPS) is a group of rare metabolic diseases associated with reduced life expectancy and a substantial unmet medical need. Immunomodulatory drugs could be a relevant treatment approach for MPS patients, although they are not licensed for this population. Therefore, we aim to pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiesinger, Anna-Maria, Bigger, Brian, Giugliani, Roberto, Lampe, Christina, Scarpa, Maurizio, Moser, Tobias, Kampmann, Christoph, Zimmermann, Georg, Lagler, Florian B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221776/ https://www.ncbi.nlm.nih.gov/pubmed/37242808 http://dx.doi.org/10.3390/pharmaceutics15051565

Ejemplares similares

RETRACTED: Wiesinger et al. An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis. Pharmaceutics 2023, 15, 1565
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy
por: Wiesinger, Anna-Maria, et al.
Publicado: (2022)

Individual Treatment Trials—Do Experts Know and Use This Option to Improve the Treatability of Mucopolysaccharidosis?
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
por: Braunlin, Elizabeth A., et al.
Publicado: (2011)

Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Bodamer, Olaf, et al.
Publicado: (2017)

Respiratory and sleep disorders in mucopolysaccharidosis
por: Berger, Kenneth I., et al.
Publicado: (2012)

Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome)
por: Kampmann, Christoph, et al.
Publicado: (2016)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2021)

Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease
por: Scarpa, Maurizio, et al.
Publicado: (2011)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Diagnostic and treatment strategies in mucopolysaccharidosis VI
por: Vairo, Filippo, et al.
Publicado: (2015)

Open issues in Mucopolysaccharidosis type I-Hurler
por: Parini, Rossella, et al.
Publicado: (2017)

Easy‐to‐use algorithm would provide faster diagnoses for mucopolysaccharidosis type I and enable patients to receive earlier treatment
por: Tylki‐Szymańska, Anna, et al.
Publicado: (2018)

International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome
por: Parini, Rossella, et al.
Publicado: (2018)

Assessment of Sleep in Children with Mucopolysaccharidosis Type III
por: Mahon, Louise Victoria, et al.
Publicado: (2014)

Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)
por: Poswar, Fabiano de Oliveira, et al.
Publicado: (2022)

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012)

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I
por: Giugliani, Roberto, et al.
Publicado: (2021)

An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III
por: Cross, Elaine M, et al.
Publicado: (2014)

Comparison of Rebound Tonometry, Perkins Applanation Tonometry and Ocular Response Analyser in Mucopolysaccharidosis Patients
por: Wasielica-Poslednik, Joanna, et al.
Publicado: (2015)

Brain RNA-Seq Profiling of the Mucopolysaccharidosis Type II Mouse Model
por: Salvalaio, Marika, et al.
Publicado: (2017)

Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type II
por: Gleitz, Hélène F. E., et al.
Publicado: (2017)

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I
por: Giugliani, Roberto, et al.
Publicado: (2017)

Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study
por: Zanetti, Alessandra, et al.
Publicado: (2019)

Recommendations on clinical trial design for treatment of Mucopolysaccharidosis Type III
por: Ghosh, Arunabha, et al.
Publicado: (2017)

Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
por: Ghosh, Arunabha, et al.
Publicado: (2019)

Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues
por: Hendriksz, Christian J., et al.
Publicado: (2016)

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
por: Horgan, Claire, et al.
Publicado: (2022)

Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome)
por: Mumford, Rachel A., et al.
Publicado: (2015)

Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management
por: Solanki, Guirish A., et al.
Publicado: (2013)

Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB
por: Wilkinson, Fiona L., et al.
Publicado: (2012)

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study
por: Hendriksz, Christian J., et al.
Publicado: (2014)

Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy
por: Pal, Abhijit Ricky, et al.
Publicado: (2018)

Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure
por: Langereis, Eveline J, et al.
Publicado: (2013)

Transition of patients with mucopolysaccharidosis from paediatric to adult care
por: Lampe, C., et al.
Publicado: (2019)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in Germany
por: Dilger, Hansjörg, et al.
Publicado: (2013)

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Ficicioglu, Can, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gbermh9qv4be79qoet4imorikb